1. Home
  2. DFDV vs ELTX Comparison

DFDV vs ELTX Comparison

Compare DFDV & ELTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DFDV

DeFi Development Corp.

N/A

Current Price

$3.09

Market Cap

93.4M

Sector

Finance

ML Signal

N/A

Logo Elicio Therapeutics Inc.

ELTX

Elicio Therapeutics Inc.

N/A

Current Price

$3.12

Market Cap

81.2M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DFDV
ELTX
Founded
2018
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.4M
81.2M
IPO Year
2022
2014

Fundamental Metrics

Financial Performance
Metric
DFDV
ELTX
Price
$3.09
$3.12
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$45.00
$18.00
AVG Volume (30 Days)
539.9K
256.7K
Earning Date
05-13-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
39.29
EPS
N/A
N/A
Revenue
$2,099,660.00
$2,301,000.00
Revenue This Year
$32.58
N/A
Revenue Next Year
$23.65
N/A
P/E Ratio
N/A
N/A
Revenue Growth
4.82
N/A
52 Week Low
$2.44
$2.66
52 Week High
$20.30
$16.00

Technical Indicators

Market Signals
Indicator
DFDV
ELTX
Relative Strength Index (RSI) 57.82 40.27
Support Level $3.04 $2.72
Resistance Level $3.35 $3.28
Average True Range (ATR) 0.19 0.17
MACD 0.06 0.15
Stochastic Oscillator 71.74 61.61

Price Performance

Historical Comparison
DFDV
ELTX

About DFDV DeFi Development Corp.

DeFi Development Corp is a U.S. company committed to building its treasury around Solana (SOL), a fast-growing blockchain infrastructure platform. This equity delivers shareholders tangible exposure to SOL price movement and staking rewards, making the firm a proxy for the Solana ecosystem. The treasury extends to running its own validator infrastructure, allowing DFDV to actively participate in and benefit from the Solana network expansion. The firm has two segments: Digital Asset Treasury ("Treasury") and Real Estate Platform ("Real Estate"). The company generates the majority of its revenue from the Treasury segment.

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company advancing novel immunotherapies for the treatment of cancer, including mKRAS-positive pancreatic cancer, colorectal cancer (CRC), lung cancer, and other mKRAS-positive cancers. The Company focuses on developing effective, off-the-shelf immunotherapies using its proprietary Amphiphile (AMP) technology, which aims to enhance the education, activation, and amplification of cancer-specific T cells to promote durable cancer immunosurveillance. Its clinical pipeline includes ELI-002 7P, a lymph node-targeted cancer immunotherapy currently being evaluated in a Phase 2 study for mKRAS pancreatic ductal adenocarcinoma (PDAC), a common form of pancreatic cancer.

Share on Social Networks: